EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATION ANALYSES IN TUMOR AND PLASMA SAMPLES FROM A PHASE IV, SINGLE-ARM STUDY OF FIRST-LINE GEFITINIB IN CAUCASIAN PATIENTS WITH EGFR MUTATION-POSITIVE, ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC)

被引：0

作者：

Douillard, Jean-Yves ^{[1
]}

Ostoros, Gyula ^{[2
]}

Cobo, Manuel ^{[3
]}

Ciuleanu, Tudor ^{[4
]}

Mccormack, Rose ^{[7
]}

Webster, Alan ^{[5
]}

Milenkova, Tsveta ^{[6
]}

机构：

[1] Ico R Gauducheau, St Herblain, France

[2] Koranyi Natl Inst Tb & Pulmonol, Budapest, Hungary

[3] Hru Carlos Haya, Malaga, Spain

[4] Prof Dr Ion Chiricuta Inst Oncol, Cluj Napoca, Romania

[5] Astrazeneca, Biometr & Informat Sci, Cambridge, England

[6] Astrazeneca, Res & Dev, Cambridge, England

[7] Astrazeneca, Personalised Healthcare, Luton, Beds, England

来源：

JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷

关键词：

EGFR mutation; gefitinib; NSCLC; Caucasian; circulating-free DNA;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P3.11-020

引用

页码：S1194 / S1195

页数：2

共 50 条

[31] PHASE II STUDY OF GEFITINIB AND INSERTED CISPLATIN PLUS DOCETAXEL AS A FIRST-LINE TREATMENT FOR ADVANCED NON-SMALL-CELL LUNG CANCER HARBORING AN EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVATING MUTATION [J].

Ohe, Yuichiro ;

Kanda, Shintaro ;

Horinouchi, Hidehito ;

Fujiwara, Yutaka ;

Nokihara, Hiroshi ;

Yamamoto, Noboru ;

Sekine, Ikuo ;

Kunitoh, Hideo ;

Kubota, Kaoru ;

Tamura, Tomohide .

JOURNAL OF THORACIC ONCOLOGY, 2013, 8 :S867-S867

[32] Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study [J].

Schuler, A. ;

Huser, J. ;

Schmid, S. ;

Schar, S. ;

Scherz, A. ;

Gautschi, O. ;

Mauti, L. ;

von Briel, T. ;

Waibel, C. ;

Pankovics, J. ;

Mark, M. T. ;

Rothschild, S. I. ;

Addeo, A. ;

Janthur, W. D. ;

Siano, M. ;

Boos, L. ;

Britschgi, C. ;

Fruh, M. .

LUNG CANCER, 2024, 187

[33] Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT) [J].

Sakata, Yoshihiko ;

Sakata, Shinya ;

Oya, Yuko ;

Tamiya, Motohiro ;

Suzuki, Hidekazu ;

Shibaki, Ryota ;

Okada, Asuka ;

Kobe, Hiroshi ;

Matsumoto, Hirotaka ;

Yokoi, Takashi ;

Sato, Yuki ;

Uenami, Takeshi ;

Saito, Go ;

Tsukita, Yoko ;

Inaba, Megumi ;

Ikeda, Hideki ;

Arai, Daisuke ;

Maruyama, Hirotaka ;

Hara, Satoshi ;

Tsumura, Shinsuke ;

Morinaga, Jun ;

Sakagami, Takuro .

EUROPEAN JOURNAL OF CANCER, 2021, 159 :144-153

[34] Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer [J].

Park, Keunchil ;

Bennouna, Jaafar ;

Boyer, Michael ;

Hida, Toyoaki ;

Hirsh, Vera ;

Kato, Terufumi ;

Lug, Shun ;

Mok, Tony ;

Nakagawa, Kazuhiko ;

O'Byrne, Kenneth ;

Paz-Ares, Luis ;

Schuler, Martin ;

Sibilotru, Denis Moro ;

Tan, Eng-Huat ;

Tanaka, Hiroshi ;

We, Yi-Long ;

Yang, James C-H ;

Zhang, Li ;

Zhou, Caicun ;

Maerten, Angela ;

Tang, Wenbo ;

Yamamoto, Nobuyuki .

LUNG CANCER, 2019, 132 :126-131

[35] First-line osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status [J].

Takamizawa, Shigemasa ;

Okuma, Yusuke ;

Kato, Yasuhiro ;

Hakozaki, Taiki ;

Kitagawa, Shingo ;

Zenke, Yoshitaka .

FUTURE ONCOLOGY, 2021, 18 (03) :291-300

[36] Comparison of efficacy of gefitinib and osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer in patients with poor performance status [J].

Nakashima, Kazuhisa ;

Kodama, Hiroaki ;

Murakami, Haruyasu ;

Takahashi, Toshiaki ;

Kawakado, Keita ;

Yanagawa, Takashi ;

Kitani, Kashu ;

Hottta, Takamasa ;

Abe, Masaaki ;

Hamai, Kosuke ;

Tanimoto, Takuya ;

Ishikawa, Nobuhisa ;

Tamura, Tomoki ;

Kuyama, Shoichi ;

Isobe, Takeshi ;

Tsubata, Yukari .

RESPIRATORY INVESTIGATION, 2024, 62 (06) :1137-1141

[37] Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer [J].

Su, Po-Lan ;

Wu, Yi-Lin ;

Chang, Wei-Yuan ;

Ho, Chung-Liang ;

Tseng, Yau-Lin ;

Lai, Wu-Wei ;

Su, Wu-Chou ;

Lin, Chien-Chung ;

Yang, Szu-Chun .

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10

[38] First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis [J].

Holleman, Marscha S. ;

van Tinteren, Harm ;

Groen, Harry J. M. ;

Al, Maiwenn J. ;

Uyl-de Groot, Carin A. .

ONCOTARGETS AND THERAPY, 2019, 12 :1413-1421

[39] First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study [J].

Igawa, Satoshi ;

Fukui, Tomoya ;

Kasajima, Masashi ;

Ono, Taihei ;

Ozawa, Takahiro ;

Kakegawa, Mikiko ;

Kusuhara, Seiichiro ;

Sato, Takashi ;

Nakahara, Yoshiro ;

Hisashi, Mitsufuji ;

Sasaki, Jiichiro ;

Naoki, Katsuhiko .

INVESTIGATIONAL NEW DRUGS, 2022, 40 (02) :430-437

[40] Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study [J].

Hochmair, Maximilian J. ;

Morabito, Alessandro ;

Hao, Desiree ;

Yang, Cheng-Ta ;

Soo, Ross A. ;

Yang, James C-H ;

Gucalp, Rasim ;

Halmos, Balazs ;

Wang, Lara ;

Golembesky, Amanda ;

Maerten, Angela ;

Cufer, Tanja .

FUTURE ONCOLOGY, 2018, 14 (27) :2861-2874

← 1 2 3 4 5 →